Check out your Company Bowl for anonymous work chats.
We at Gilead Sciences support our colleagues at Kite Pharma and their dedication to driving cancer research that has the potential to improve the lives of people living with the disease around the world. #WorldCancerDay
CAR T cell immunotherapy named the Advance of the Year in annual ASCO report. We’re proud to play a role in advancing cell therapy: http://glassdoor.com/slink.htm?key=vQssQ
We’re proud to join more than 500 organizations in support of the U=U Consensus Statement. Learn more about the U=U campaign and the full Consensus Statement: http://glassdoor.com/slink.htm?key=vQU3B.
Throughout 2018 we will be sharing a quick glimpse into our working lives here at Gilead. Meet Lauryn from the Regulatory Affairs team in Foster City http://glassdoor.com/slink.htm?key=vQUsV . #gileadlife
Gilead's subsidiary Kite announces clinical collaboration with Pfizer to evaluate investigational treatment combination in large B-cell lymphoma. Find out more: http://glassdoor.com/slink.htm?key=vQURO
Throughout 2018 we will sharing a quick glimpse into our working lives here at Gilead. Please meet Ligia from the Biometrics team based in Foster City. #gileadlife http://glassdoor.com/slink.htm?key=vQgK0
The Medical Affairs team at Gilead is a team of highly skilled medical and non-medical professionals commitment to helping patients maximize the benefits they receive from our therapeutics through the ethical generation, education, differentiation and communication of scientific information. If you have a clinical background and wish to support a worldwide group of patients in a fast paced, career oriented environment, please get in touch. http://glassdoor.com/slink.htm?key=vQgDE
To honour our commitment to bringing innovative therapies to people around the world we are creating new career opportunities throughout 2018. Hear what working at Gilead means to our colleagues: http://glassdoor.com/slink.htm?key=vQ2oz Meaningful Careers. Inclusive Environment. http://glassdoor.com/slink.htm?key=vQ2of
Wishing you a happy new year and thank you for following us in 2017. Throughout 2018 we will remain committed to bringing innovative therapies to people around the world.
We are committed to innovation and addressing unmet medical needs around the world. Learn more about Gilead from our Executive Chairman, John Martin, in this article from The Wall Street Journal: http://glassdoor.com/slink.htm?key=vQuuW.
